Dirk Behringer

Title: Dirk Behringer: Innovator in Genotyping and Toxicity Prediction

Introduction

Dirk Behringer is a notable inventor based in Bochum, Germany. He has made significant contributions to the field of pharmacogenomics, particularly in the area of predicting adverse effects from microtubule-stabilizing agents. His work is crucial for improving patient safety and treatment efficacy.

Latest Patents

Dirk Behringer holds a patent titled "ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity." This patent outlines methods for identifying subjects at an increased risk of developing adverse side effects from microtubule-stabilizing agents. The methods involve determining the presence of ABCB1 predictive polymorphisms, such as 2677G>T/A and 3435C>T, which indicate a higher likelihood of toxicity. The patent also includes methods for modifying therapy based on these genetic markers, along with kits and isolated nucleic acid molecules for practical application.

Career Highlights

Throughout his career, Dirk Behringer has worked with prominent organizations, including the United States Department of Health and Human Services and Universitätsklinikum Freiburg. His research has focused on enhancing the understanding of genetic factors that influence drug response, thereby contributing to personalized medicine.

Collaborations

Dirk has collaborated with esteemed colleagues such as Tristan M. Sissung and Klaus Mross. These partnerships have facilitated advancements in the field and have led to a deeper understanding of the genetic underpinnings of drug toxicity.

Conclusion

Dirk Behringer's innovative work in genotyping and toxicity prediction has the potential to transform patient care by enabling more personalized treatment strategies. His contributions are vital for advancing the field of pharmacogenomics and improving therapeutic outcomes.